Results 131 to 140 of about 3,893,535 (160)

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy. [PDF]

Front Endocrinol (Lausanne)
Stemann Lau T, Bossen L, Rasmussen DGK, Genovese F, Karsdal M, Arveschoug AK, Grønbæk H, Dam G.   +7 more
europepmc   +1 more source

Multicycle Dosimetric Behavior and Dose-Effect Relationships in [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy. [PDF]

J Nucl Med
Kayal G, Roseland ME, Wang C, Fitzpatrick K, Mirando D, Suresh K, Wong KK, Dewaraja YK.   +7 more
europepmc   +1 more source

An ACTH-Producing Neuroendocrine Tumor: Clinical Course of Multidisciplinary Therapy Including Peptide Receptor Radionuclide Therapy - A Case Report. [PDF]

Case Rep Oncol
Koizumi T, Sato A, Kitajima K, Yamazaki M, Kanazawa S, Notake T, Sato Y, Kobayashi S, Iwaya M, Umeda T, Komatsu M.   +10 more
europepmc   +1 more source

Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours. [PDF]

Br J Surg
Hallet J, Søreide K.
europepmc   +1 more source

Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. [PDF]

J Neuroendocrinol
Kuiper J, Zoetelief E, Brabander T, de Herder WW, Hofland J.   +4 more
europepmc   +1 more source

Retraction: Efficacy and Safety of Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. [PDF]

Cureus
Zhao J, Pei X, Li Y.
europepmc   +1 more source

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. [PDF]

J Nucl Med
Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA.   +6 more
europepmc   +1 more source

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

BMC Cancer
Puranik AD, Dev ID, Yadav S, Rangarajan V, Agrawal A, Basu S, Chaudhari VA, Ramaswamy A, Ostwal V, Bhandare MS, Shrikhande SV, Parghane RV, Bhargava P, Bal MM, Yadav S, Patkar S, Goel M, Purandare NC, Shah S, Choudhury S, Ghosh S, Venkatachalam M.   +21 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Gujarathi R, Tobias J, Abou Azar S, Keutgen XM, Liao CY.   +4 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

Ann Surg Oncol
Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Menda Y, Bushnell D, Bellizzi AM, Ear PH, O'Dorisio MS, O'Dorisio TM, Dillon JS, Howe JR.   +11 more
europepmc   +1 more source